Searched for
JANSSEN BIOTECH
Biocon settles with Janssen to commercialise biosimilar products in Europe, Canada, JapanBiocon Biologics has entered into a settlement and licence agreement with Janssen Biotech Inc, Janssen Sciences Ireland, and Johnson & John...- Stocks in news: Suven Pharma, MOIL, Adani stocks, ICICI Lombard, VedantaSuven Pharmaceuticals and Cohance Lifesciences signed a definitive agreement to merge their businesses, which will further strengthen the f...
- Covaxin gets WHO nod for emergency use, move to ease travel for those who took made-in-India vaccineCovaxin was also reviewed by WHO's Strategic Advisory Group of Experts on Immunisation (SAGE), which recommended the use of the vaccine in ...
- Covaxin gets WHO approval for emergency use listingWHO's TAG is an independent advisory group that provides recommendations to the WHO on whether a Covid 19 vaccine can be listed for emergen...
- Bharat Biotech's Covaxin gets WHO okay for emergency useHyderabad-based Bharat Biotech, which has developed Covaxin, submitted EOI (Expression of Interest) to the WHO on April 19 for the vaccine'...
- Bharat Biotech submits additional data to WHOIn its meeting on October 26, the TAG had sought "additional clarification" from Bharat Biotech to conduct a final risk-benefit assessment ...
- We trust Indian industry, Bharat Biotech has been submitting data regularly, very quickly: WHO official on Covaxin EULBharat Biotech's Covaxin and AstraZeneca and Oxford University's Covishield are the two widely used vaccines in India.
- WHO seeks 'additional clarifications' from Bharat Biotech for Covaxin to conduct final 'risk-benefit assessment'"The TAG met today (26 October 2021) and decided that additional clarifications from the manufacturer are needed to conduct a final EUL ris...
- Technical Advisory Group seeks additional clarification on Covaxin for Emergency Use ListingWhile the WHO has so far approved Covid-19 vaccines of Pfizer-BioNTech, AstraZeneca-SK Bio/Serum Institute of India, Johnson & Johnson-Jans...
- Review of Covaxin by WHO underway; expect a recommendation within 24 hours: spokesperson"On COVAXIN, the technical advisory group that reviews all the data for a potential emergency use listing are indeed reviewing that data to...
- WHO's advisory group set to meet on October 26 to decide on Covaxin EUL approvalWhile the WHO has so far approved Covid-19 vaccines of Pfizer-BioNTech, AstraZeneca-SK Bio/Serum Institute of India, Johnson & Johnson-Jans...
- WHO may take a call on Covaxin todayThe company said last week that it was diligently working with the WHO to obtain Emergency Use Listing (EUL) at the earliest adding it is n...
- WHO to decide on Bharat Biotech's Covaxin clearance in OctoberSoumya Swaminathan, WHO's chief scientist, told ET that the "process is ongoing".
- WHO to review Covaxin; emergency use approval may come by mid-SeptemberThe WHO global advisory committee on vaccine safety will assess immunogenicity, vaccine safety and vaccine effectiveness of Covaxin, a cruc...
- Approvals for J&J jabs soon, pricing to be reasonable: Vaccine Task Force co-chair K Vijay RaghavanGlobal vaccine maker Johnson and Johnson has applied to India’s drug regulator seeking permission to conduct phase 3 clinical trial of its ...
- Johnson & Johnson set to begin India trial of its single-shot vaccine, says reportThe U.S. drugs and healthcare giant's vaccine is currently approved for use in the United States, the European Union and other nations incl...
- Johnson & Johnson requests emergency authorization for Covid vaccineJ&J subsidiary Janssen Biotech "has submitted an application to the US Food and Drug Administration (FDA) requesting Emergency Use Authoriz...
- UK government strikes 90 million dose deal for two potential COVID-19 vaccine candidatesIf the vaccines are found safe and successful in clinical trials, both could be delivered to the UK in mid-2021 and would be given first to...
- Glenmark Pharma gets USFDA nod for prostate cancer treatment drugShares of Glenmark Pharma were trading 0.15 per cent higher at Rs 286.00 apiece on the BSE.
- Genmab inks $1.1 bn deal with Johnson & JohnsonDanish pharma firm Genmab has said that it had reached a deal worth up to $1.1 bn with US drug giant Johnson & Johnson.
Load More
